Immunological Significance of Alternative Splicing Prognostic Signatures for Bladder Cancer

Overview

Journal Heliyon

Specialty Social Sciences

Date 2022 Mar 4

PMID 35243106

Authors

Xinyun Li

Lin Yang

Wei Huang

Bo Jia

Yu Lai

Affiliations

Soon will be listed here.

Abstract

Background: Bladder cancer (BLCA) is the most common malignant tumor in the genitourinary system, and the complex tumor microenvironment (TME) of BLCA is the main factor in its difficult treatment. Accumulated evidence supports that alternative splicing (AS) events frequently occur in cancer and are closely related to the TME. Therefore, there is an urgent need to comprehensively analyze the prognostic value of AS events in BLCA.

Method: The clinical, transcriptome and AS data of BLCA were downloaded from the Cancer Genome Atlas database, and a Cox proportional hazard regression model and LASSO regression were used to establish a prognostic signature. Then, the prognostic value of the signature was verified by clinical survival status, clinicopathologic features, tumor immune microenvironment (TIME), and immune checkpoint. Next, we screened the AS-related genes with the largest expression differences between tumor and normal samples by gene differential expression analysis. Finally, the regulatory network of AS-splicing factors (SFs) was established to unravel the potential regulatory mechanism of AS events in BLCA.

Results: A BLCA prognostic signature related to seven AS events was constructed, and the prognostic value of the signature was also verified from multiple perspectives. Moreover, there was significant abnormal expression of , a gene implicated in AS events, the expression of which was associated with the survival, clinicopathological features, TIME, and immunotherapy of BLCA, suggesting that it has potential clinical application value. Furthermore, the AS-SF regulatory network indicated that splicing factors (PRPF39, LUC7L, HSPA8 and DDX21) might be potential biomarkers of BLCA.

Conclusions: Our study revealed the potential role of AS events in the prognosis, TIME and immunotherapy of BLCA and yielded new insights into the molecular mechanisms of and personalized immunotherapy for BLCA.

Citing Articles

Alternative splicing regulation and its therapeutic potential in bladder cancer.

Li L, Jin T, Hu L, Ding J Front Oncol. 2024; 14:1402350.

PMID: 39132499 PMC: 11310127. DOI: 10.3389/fonc.2024.1402350.

References

Ye Y, Peng L, Vattai A, Deuster E, Kuhn C, Dannecker C . Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR). J Cancer Res Clin Oncol. 2020; 146(9):2189-2203. PMC: 7382663. DOI: 10.1007/s00432-020-03272-0. View

Ariafar A, Vahidi Y, Fakhimi M, Asadollahpour A, Erfani N, Faghih Z . Prognostic significance of CD4-positive regulatory T cells in tumor draining lymph nodes from patients with bladder cancer. Heliyon. 2020; 6(12):e05556. PMC: 7711140. DOI: 10.1016/j.heliyon.2020.e05556. View

Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T . Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut. 2004; 53(8):1151-8. PMC: 1774140. DOI: 10.1136/gut.2003.028787. View

Inoue R, Hirohashi Y, Kitamura H, Nishida S, Murai A, Takaya A . GRIK2 has a role in the maintenance of urothelial carcinoma stem-like cells, and its expression is associated with poorer prognosis. Oncotarget. 2017; 8(17):28826-28839. PMC: 5438695. DOI: 10.18632/oncotarget.16259. View

Bielli P, Panzeri V, Lattanzio R, Mutascio S, Pieraccioli M, Volpe E . The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients with Non-muscle-Invasive Bladder Cancer. Clin Cancer Res. 2018; 24(21):5422-5432. DOI: 10.1158/1078-0432.CCR-17-3850. View

Eckstein M, Wirtz R, Pfannstil C, Wach S, Stoehr R, Breyer J . A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget. 2018; 9(19):15001-15014. PMC: 5871092. DOI: 10.18632/oncotarget.24531. View

Yano T, Zissel G, Shin S, Satoh H, Ichikawa T . Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett. 2002; 518(1-3):154-8. DOI: 10.1016/s0014-5793(02)02689-3. View

Yeon S, Jo Y, Choi E, Kim M, Yoo N, Lee S . Frameshift Mutations in Repeat Sequences of ANK3, HACD4, TCP10L, TP53BP1, MFN1, LCMT2, RNMT, TRMT6, METTL8 and METTL16 Genes in Colon Cancers. Pathol Oncol Res. 2017; 24(3):617-622. DOI: 10.1007/s12253-017-0287-2. View

Eich M, Chaux A, Guner G, Taheri D, Mendoza Rodriguez M, Pena M . Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. Hum Pathol. 2019; 89:24-32. DOI: 10.1016/j.humpath.2019.04.003. View

10.

Pan Q, Shai O, Lee L, Frey B, Blencowe B . Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008; 40(12):1413-5. DOI: 10.1038/ng.259. View

11.

Pradella D, Naro C, Sette C, Ghigna C . EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017; 16(1):8. PMC: 5282733. DOI: 10.1186/s12943-016-0579-2. View

12.

Li Z, Zheng Z, Wei Z, Zhang L, Li F, Lin L . Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics. 2019; 9(25):7648-7665. PMC: 6831462. DOI: 10.7150/thno.36585. View

13.

Kim J, Patel M, Mangraviti A, Kim E, Theodros D, Velarde E . Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clin Cancer Res. 2016; 23(1):124-136. PMC: 5735836. DOI: 10.1158/1078-0432.CCR-15-1535. View

14.

Baralle F, Giudice J . Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017; 18(7):437-451. PMC: 6839889. DOI: 10.1038/nrm.2017.27. View

15.

Su X, Lashinger E, Leon L, Hoffman B, Hieble J, Gardner S . An excitatory role for peripheral EP3 receptors in bladder afferent function. Am J Physiol Renal Physiol. 2008; 295(2):F585-94. DOI: 10.1152/ajprenal.90273.2008. View

16.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

17.

Zhang D, Liu X, Xu X, Xu J, Yi Z, Shan B . HPCAL1 promotes glioblastoma proliferation via activation of Wnt/β-catenin signalling pathway. J Cell Mol Med. 2019; 23(5):3108-3117. PMC: 6484330. DOI: 10.1111/jcmm.14083. View

18.

Jin Y, Hu P . Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women. Cancers (Basel). 2020; 12(5). PMC: 7281139. DOI: 10.3390/cancers12051076. View

19.

Roberts J, von der Maase H, Sengelov L, Conte P, Dogliotti L, Oliver T . Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006; 17 Suppl 5:v118-22. DOI: 10.1093/annonc/mdj965. View

20.

Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View